NTHI NeOnc Technologies Holdings, Inc.
Company Analysis
Latest News
🔴 NTHI is trading 5.1% down today on $75M financing overhang despite UAE IND authorization
NTHI is trading 5.1% down at $4.63 as a potential $75 million share issuance weighs on the stock, offsetting positive regulatory news from the Middle East. •...
NTHI Receives UAE IND Approval for Brain Cancer Candidate NEO100, Expanding Global Trials
NeOnc Technologies Holdings announced it has received Investigational New Drug (IND) status from the Department of Health – Abu Dhabi (DOH) for its lead...
🔴 NTHI is trading 5.9% down today on profit-taking after UAE regulatory approval spike
NTHI is trading 5.9% down today at $4.81 as investors take profits following a sharp rally driven by regulatory milestones in the UAE. • The stock recently...
🟢 NTHI is trading 5.03% up today after securing UAE IND approval for NEO100
• NeOnc Technologies Holdings, Inc. (NTHI) announced on June 23, 2026, that the Abu Dhabi health authority granted IND approval for NEO100 for multiple adult...
🔴 NeOnc Technologies Holdings, Inc. is trading 8.2% down today on profit-taking after UAE Phase 2 trial approval
NeOnc Technologies Holdings, Inc. is trading at $4.84, down 8.2% as investors take profits following a significant regular-session rally on June 18, 2026. •...
NTHI Secures UAE Regulatory Approval for Brain Cancer Drug NEO212
NeOnc Technologies Holdings, Inc. announced it has received Investigational New Drug (IND) approval from the Department of Health – Abu Dhabi (DOH) for its...
🟢 NeOnc Technologies Holdings, Inc. is trading 8.3% up today as UAE IND approval rally resumes after profit-taking
NeOnc Technologies Holdings, Inc. is trading 8.3% up today at $5.21 as buyers step back in following yesterday’s profit-taking. • The stock had pulled back on...
🔴 NeOnc Technologies Holdings, Inc. is trading 5.7% down today as traders lock in profits following its UAE IND approval rally
NeOnc Technologies Holdings, Inc. is trading 5.7% down at $4.89 today, pulling back from a sharp rally driven by positive regulatory news in the Middle...
🔴 NeOnc Technologies Holdings, Inc. pulls back 9.5% after sharp prior-session rally driven by UAE IND approval for NEO212
NeOnc Technologies Holdings, Inc. is trading at $4.69 (9.5% down) in pre-market, pulling back after a sharp prior-session rally. • This follows the company...
🔴 NeOnc Technologies Holdings, Inc. makes sharp 12.9% drop
NTHI is trading at $4.51, down 12.9% versus the comparison close of $5.18 during after-hours. This is a price-movement alert; no separate company-specific...
NeOnc's $5M Preferred Stock Deal Plugs a Cash Hole — But Can Dilution-Wary Investors Stay on Board?
Shares shifted sharply as NeOnc Technologies (NTHI), a tiny clinical-stage biotech developing experimental brain cancer treatments, saw its stock whipsaw...
🔴 NeOnc Technologies Holdings, Inc. is trading 7.3% down today after a $5 million convertible preferred stock financing agreement
NeOnc Technologies Holdings, Inc. is trading at $4.80, down 7.3% in after-hours trading following the details of a $5 million private placement of Series A...
NTHI Enters Agreement for up to $5M in Convertible Preferred Stock Financing
NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement on June 10, 2026, to sell up to $5.0 million of its newly designated Series A...
🟢 NeOnc Technologies Holdings, Inc. surges 12.9% on UAE IND clearance for NEO212 Phase 2 brain trial
- NeOnc Technologies Holdings, Inc. is trading 12.9% up at $5.09 today, after the Department of Health – Abu Dhabi granted Investigational New Drug (IND)...